Autonomous University of Barcelona

HistoSonics' Edison System Treats First Pancreatic Tumor Patients in GANNON Trial

5 months ago

• HistoSonics announced the successful treatment of the first pancreatic tumor patients using its Edison Histotripsy System in the GANNON trial, marking its expansion into pancreatic tumor therapy. • The GANNON trial evaluates the safety of histotripsy, a non-invasive technology using focused ultrasound to destroy targeted tumor tissue, in patients with inoperable pancreatic adenocarcinoma. • Pancreatic cancer is a difficult-to-treat disease with a high mortality rate and limited surgical options, making new treatment modalities like histotripsy urgently needed. • Histotripsy's novel mechanism targets both the tumor and surrounding fibrotic tissue, offering hope for patients with advanced pancreatic cancer, who often have limited treatment options.